U.S. STOCKS ON THE MOVE-Lemonade, New York Times, Johnson Controls
U.S. STOCKS ON THE MOVE-McDonald's, Lumentum, Humana
Biohaven falls as US FDA rejects rare nerve disease drug application
U.S. RESEARCH ROUNDUP- Equifax, Johnson & Johnson, Morgan Stanley
Biohaven climbs as FDA says no advisory committee needed for genetic disorder drug
Brief: Biohaven Files Prospectus Related To Register Resale Of Up To 3.6 Million Common Shares
U.S. RESEARCH ROUNDUP- Advanced Drainage Systems, Assurant, Chipotle Mexican Grill
Biohaven Ltd reports results for the quarter ended June 30 - Earnings Summary
Brief: Biohaven Reports Second Quarter 2025 Financial Results
Factbox: Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
Brief: Biohaven Enrolls First Patient Into Phase 2/3 Trial In Early Parkinson's Disease
Brief: Biohaven Presents Oncology Program Updates And Preliminary Clinical Data
U.S. STOCKS ON THE MOVE-Plug Power, BGC Group, Paramount Group
U.S. STOCKS ON THE MOVE-Sable Offshore, Regeneron, Plug Power
U.S. STOCKS ON THE MOVE-Novavax, Reddit, BorgWarner
Biohaven falls after RBC downgrades on regulatory uncertainty
U.S. STOCKS ON THE MOVE-Xponential Fitness, Phillips 66, Amazon.com
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Boeing, Abbott
Biohaven drops after FDA extends review period for genetic disease drug